Patricia B. Prichep
Net Worth
Last updated:
What is Patricia B. Prichep net worth?
The estimated net worth of Ms. Patricia B. Prichep is at least $7,946,073 as of 8 May 2024. She owns shares worth $2,004,973 as insider and has received compensation worth at least $5,941,100 in CEL-SCI Corporation.
What is the salary of Patricia B. Prichep?
Ms. Patricia B. Prichep salary is $270,050 per year as Senior Vice President of Operations & Corporation Sec. in CEL-SCI Corporation.
How old is Patricia B. Prichep?
Ms. Patricia B. Prichep is 74 years old, born in 1951.
What stocks does Patricia B. Prichep currently own?
As insider, Ms. Patricia B. Prichep owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| CEL-SCI Corporation (CVM) | Senior Vice President of Operations & Corporation Sec. | 232,326 | $8.63 | $2,004,973 |
What does CEL-SCI Corporation do?
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Patricia B. Prichep insider trading
CEL-SCI Corporation
CEL-SCI key executives
CEL-SCI Corporation executives and other stock owners filed with the SEC:
- Dr. Daniel H. Zimmerman Ph.D. (84) Senior Vice President of Research & Cellular Immunology
- Dr. Eyal Talor Ph.D. (69) Chief Scientific Officer
- Mr. Geert R. Kersten (66) Chief Executive Officer, Principal Accounting & Financial Officer, Treasurer and Director
- Mr. John Cipriano (83) Senior Vice President of Regulatory Affairs
- Ms. Patricia B. Prichep (74) Senior Vice President of Operations & Corporation Sec.